Refine by
Patient Respiratory Articles & Analysis
53 news found
Vitalograph has joined forces with MedM Inc. to further enhance patient respiratory monitoring experience with digital health capabilities. ...
It is a point-of-care device for assessing airway inflammation in patients with respiratory problems. With over 45 million NIOX® tests undertaken to date, the system is used by healthcare professionals around the world to help improve asthma care. ...
It can aid in the diagnosis of asthma and COPD and can also help identify patients who are at risk of progression to COPD. [1] The tremoflo® C-100 assesses respiratory function through simple tidal breathing and can be a valuable tool when compiling a detailed picture of respiratory function. It is particularly useful in enabling the very ...
Vitalograph, a global leader in the development and production of respiratory diagnostic solutions and clinical trial services, has launched the Vitalograph tremoflo® C-100 at this year’s ATS International Conference, taking place in Washington. ...
(NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
(NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
The initial targeted indications include: Post-operative Respiratory Depression. Respiratory depression is common in patients recovering from surgery and anesthesia. ...
N8 Medical, LLC (N8 Medical) today announced its first-in-human clinical trials of its flagship CeraShield™ endotracheal tube (CeraShield™ ETT) for intensive care unit patients expected to require mechanical ventilation for more than 48 hours. ...
Enalare Therapeutics Inc., a biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening critical care conditions, announced today that it has completed a propofol induced respiratory depression study with its lead compound ENA001, having achieved the targeted primary endpoint. ...
Oxygen is a life-saving therapeutic gas, which is often used to treat patients with severe pneumonia and other respiratory diseases. Oxygen generator is an electric medical equipment. It first inhales air, removes nitrogen, then generates a continuous oxygen source, and delivers concentrated oxygen to patients who need ...
These analyses included patients ≥65 years old, those with co-morbidities associated with worse COVID-19 outcomes, and those who, at baseline, despite receiving low flow oxygen, had clinical signs of compromised respiratory function (defined as oxygen saturation of ≤ 92% or respiratory rate ≥ 21 breaths/min). These analyses showed ...
“With this technology, we can take a step forward in diagnosis and the allocation of different treatments in patients with chronic, severe respiratory failure,” De Backer summarizes. ...
ByFluidda
Etienne Jornod was Executive Chairman of the Galenica and Vifor Pharma Group, delivering 25 consecutive double-digit net profit growth, supporting millions of patients, and creating thousands of jobs. On 30 September 2020, he personally acquired OM Pharma together with entrepreneurs, aiming to create a unique biopharmaceutical company based on bacteria lysates expertise. OM ...
This allows BioCardia to initiate its First-in-Human Phase I/II trial in adult patients recovering from Acute Respiratory Distress Syndrome (ARDS) due to COVID-19, with trial initiation expected in the third quarter of 2022. ...
The bronchus regenerated, much as in the esophagus, first forming a tube and later developing into a bronchus with a functional lining known as the respiratory epithelium. The respiratory epithelium was seen in about two months in the pig. This respiratory epithelium is essential to the avoidance of infections such as pneumonia. ...
MADISON, Wis., March 2, 2022 /PRNewswire/ -- Today Redox, the company driving interoperability in healthcare, has announced a partnership with Spire Health, the leading digital healthcare company for respiratory remote patient monitoring (RPM). Together, Spire Health and Redox will integrate RPM data into health system electronic medical records (EMRs) to improve ...
The updated guidelines aim to improve the quality of the spirometric measurements and improve the patient experience. Committed to usability since the very first EasyOne spirometer, NDD continues this tradition during the implementation of the spirometry 2019 update. ...